Industry: Pharmaceuticals, Biotechnology
Peplin is focused on the discovery, development and commercialisation of prescription pharmaceuticals for the treatment of cancer. Peplin’s strategy is to leverage its pipeline of novel proprietary products through collaborative development and commercialisation arrangements with international pharmaceutical companies. Peplin’s lead product is a clinical stage topical therapy for actinic keratosis and non-melanoma skin cancer. It is the subject of a US$23 million development collaboration and license agreement with Allergan, Inc. of Irvine, California for commercialisation in North and South America. Peplin retains rest of world rights for PEP005 Topical and all rights world wide to other cancer applications of ( www.peplin.com )
Peplin Limited
P.O. Box 346
Fortitude Valley, Queensland 4006
Australia
Tel: +61 7 3250 1200
Industry: Pharmaceuticals, Biotechnology
Divergence is dedicated to the discovery of effective and ecologically sound strategies for the control of parasites and other pests. The company’s initial focus is on parasitic nematodes, one of the world’s major pest groups. Nematodes are roundworms that cause billions of dollars in damage annually to numerous crops, including soybeans, cotton, strawberries, and bananas. Nematodes also cause widespread disease in animals, including infections such as heartworm in dogs and cats and intestinal worms in livestock. Nematode-induced human diseases include elephantiasis and African river blindness. ( www.divergence.com )
Divergence , Inc.
Divergence, Inc. 893 North Warson Road
St. Louis, Missouri 63141
USA
Tel: (314) 812-8052
Fax: (314) 812-8080
Industry: Pharmaceuticals, Biotechnology
Ecopia is finding novel anticancer therapies from soil-dwelling microorganisms that are one of the most prolific sources of drugs. Our current focus is to move our flagship compound ECO-4601 through Phase I clinical trials. ECO-4601 is a novel small molecule that, based on advanced animal models, crosses the blood brain barrier and is effective in significantly inhibiting primary brain tumor growth and other types of cancers. Just like well-known chemotherapies such as doxorubicin and mitomycin C, ECO-4601 comes from microorganisms that live in common soil. However, unlike these drugs that were discovered many decades ago, ECO-4601 represents a new chemical class that is derived from Ecopia’s proprietary drug discovery platform ( www.ecopiabio.com )
Ecopia BioSciences Inc.
7290 Frederick Banting
Saint-Laurent, Quebec H4S 2A1
Canada
Tel: (514) 336-2700
Fax: (514) 336-8827
Industry: Pharmaceuticals, Biotechnology
Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel treatments for cancer, inflammation, and neurodegenerative diseases. Founded in 2002, Reata is developing five distinct classes of cancer drugs licensed from leading academic institutions. The company has three drugs in Phase 1 clinical development: RTA 744 for primary brain cancers; RTA 402 for solid tumors and lymphoid malignancies; and RTA 401 for leukemias and solid tumors. Reata is matching its clinical and preclinical drug development programs with a best-of-class drug discovery platform to identify small molecule chaperones that can induce proper folding of p53, SOD, and Tau, misfolded proteins that are involved in cancer and neurodegenerative disease. ( www.reatapharma.com )
Reata Pharmaceuticals , Inc.
2801 Gateway Drive, Suite 150
Irving, Texas 75063
USA
Tel: (972) 865-2200
Fax: (214) 722-0867
Industry: Pharmaceuticals, Biotechnology
Lev is a biopharmaceutical company focused on developing and commercializing therapeutic products for the treatment of inflammatory diseases. Lev’s product candidates are based on C1-esterase inhibitor (”C1-INH”), a human plasma protein that mediates inflammation and is potentially applicable as a treatment for a range of medical indications. The Company initiated a Phase III clinical trial of its lead product candidate, C1-INH for the treatment of hereditary angioedema, in March 2005. Lev is also developing C1-INH for the treatment of selective other diseases and disorders in which inflammation is known or believed to play an underlying role. ( www.levpharma.com )
Lev Pharmaceuticals , Inc.
122 East 42Nd Street Suite 2606
New York, New York 10168
USA
Tel: (212) 682-3096
Fax: (212) 682-3994
Industry: Pharmaceuticals, Biotechnology
Founded in 1994, CDC Solutions is the leading provider of enterprise-scale document solutions for the Life Sciences industry. CDC Solutions is trusted by pharmaceutical and life sciences companies worldwide, and is poised to set the standard for the production of new drug applications (NDAs), reports, bids, proposals, technical documentation, and other mission critical information. The company’s flagship software, EZsubs Publishing Suite, offers unmatched flexibility and dexterity and is built on proven, world-class technology that transforms proprietary content into open formats such as XML and ( www.htgenomics.com )
High Throughput Genomics , Inc.
6296 East Grant Road
Tucson, Arizona 85712
USA
Tel: (520) 547-2827
Fax: (520) 547-2837
Industry: Pharmaceuticals, Biotechnology
PainCeptor Pharma is a biopharmaceutical company developing next generation therapeutic drugs for the treatment of chronic and acute pain. PainCeptor’s resources are concentrated on some of the most promising, novel, yet scientifically validated therapeutic targets within the PNS (peripheral nervous system). By focusing on modulating target receptors in the PNS, PainCeptor expects to enhance the efficacy and avoid the many detrimental side effects associated with today’s pain drugs which act primarily in the CNS. PainCeptor’s development pipeline includes two lead antagonist programs, targeting NGF/p75-TrkA and ASIC1a, and a third antagonist program targeting ASIC3. ( www.painceptor.com )
PainCeptor Pharma Corp.
7150, Albert-Einstein Suite 100
St-Laurent, Quebec H4S 2C1
Canada
Tel: (514) 337-5959
Fax: (514) 337-8689
Industry: Pharmaceuticals, Biotechnology
Arcadia Biosciences was founded in 2002 to pursue agriculture-based business opportunities that improve the environment and human health. Arcadia identifies and develops promising technologies. The company commercializes products from these technologies through channels that will deliver the most value to consumers, producers, our partners and our shareholders. We use a number of technology tools-both GM and non-GM-to develop our product portfolio, including precise genetic screening, advanced breeding techniques and genetic engineering. Our current areas of focus include: Environmental Health Technologies arrow ( www.arcadiabio.com )
Arcadia Biosciences , Inc.
202 Cousteau Place, Suite 200
Davis, California 95616
USA
Tel: (530) 756-7077
Fax: (530) 756-7027
Industry: Pharmaceuticals, Biotechnology
CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is finishing Phase IIb clinical trials for the treatment of acute migraines and related symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition. CAPNIA is funded by Vivo Ventures, Asset Management Company, Teknoinvest Management AS, Alliance Venture and Novel Bioventures. We are located in Palo Alto, California. ( www.capnia.com )
CAPNIA Inc
2445 Faber Place Suite 250
Palo Alto, California 94303
USA
Tel: (650) 213-8444
Fax: (650) 213-8383
Industry: Pharmaceuticals, Biotechnology
Attenuon, LLC is a San Diego-based clinical-stage biopharmaceutical company developing a new generation of cancer therapeutics. Attenuon’s drug candidates are designed to selectively disrupt multiple cellular processes important to tumor growth and metastasis (the spreading of tumors). Rather than indiscriminately killing both malignant and normal cells undergoing cell division, these drugs are directed at targets that are present in a broad range of tumors and the blood vessels that feed their growth. These drug candidates have the potential to be effective against many types of cancer, produce few side effects, and be suitable for long-term ( www.attenuon.com )
Attenuon , LLC
11535 Sorrento Valley Road Suite 401
San Diego, California 92121
USA
Tel: (858) 720-8797
Fax: (858) 720-1086